T-cell phenotypes associated with effective CAR T-cell therapy in postinduction vs relapsed multiple myeloma
AL Garfall, EK Dancy, AD Cohen, WT Hwang… - Blood …, 2019 - ashpublications.org
Blood advances, 2019•ashpublications.org
T-cell phenotypes associated with effective CAR T-cell therapy in postinduction vs relapsed
multiple myeloma | Blood Advances | American Society of Hematology Skip to Main Content
Advertisement Umbrella Alt Text Umbrella Alt Text Close ASH Clinical News ASH News Daily
ASH-SAP Blood Journals Blood Blood Advances Blood Neoplasia Blood Vessels, Thrombosis
& Hemostasis Hematology The Hematologist International Blood Chinese Edition Blood
Japanese Edition Blood Italian Edition Blood Latin America Edition Blood Spanish Edition ASH …
multiple myeloma | Blood Advances | American Society of Hematology Skip to Main Content
Advertisement Umbrella Alt Text Umbrella Alt Text Close ASH Clinical News ASH News Daily
ASH-SAP Blood Journals Blood Blood Advances Blood Neoplasia Blood Vessels, Thrombosis
& Hemostasis Hematology The Hematologist International Blood Chinese Edition Blood
Japanese Edition Blood Italian Edition Blood Latin America Edition Blood Spanish Edition ASH …
Key points
- T cells from patients early in myeloma therapy exhibit better fitness for CAR T manufacturing than those from relapsed/refractory patients.
- CAR T cells may be more effective if manufactured from patients before onset of relapsed/refractory disease.
ashpublications.org
